Liquid biopsy during PSMA radiation therapy
Part of Cancer, Kidney & urinary clinical trials.
This trial studies blood tests (liquid biopsies) in men with metastatic prostate cancer that no longer responds to hormone therapy or chemotherapy and who are receiving a type of radiation therapy called PSMA RLT. The goal is to see if these blood tests can provide useful information about the cancer and treatment response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic prostate cancer that has not responded to hormone therapy and one prior chemotherapy.
- Your doctor has recommended PSMA RLT (a targeted radiation therapy) and you meet its standard use criteria.
- You have had a PSMA PET/CT scan within the last 8 weeks.
- You are at least 18 years old.
- You understand German, or have someone to translate for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at tissue samples from tumors to understand how and why PSMA radioligand therapy may become less effective. If you have PSMA-avid cancer lesions that can be biopsied, the trial may help researchers find ways to improve treatment.
This trial tests a personalized form of radiation therapy that targets a protein called PSMA found on some cancer cells. It may help people whose cancer has spread or cannot be removed with surgery, and has not responded to other treatments.
This trial looks at people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. It tests a radioactive medicine (lutetium-177 PSMA) that targets prostate cancer cells, to see what factors predict a good response.
This Phase 1/2 trial tests a PSMA-targeted radioligand treatment (a drug that delivers radiation to prostate cancer cells) in men with metastatic castration-resistant prostate cancer that has gotten worse despite standard hormone therapies. It’s designed to see how the treatment works and whether it can help shrink or control cancer, while also studying safety and dosing.
This trial tests a targeted radiation drug (Lu177-PSMA) combined with procedures that treat liver tumors directly (like ablation or radiation). It is for men with prostate cancer that has spread to the liver and is no longer responding to hormone therapy. The goal is to see if this combination works better together.
This early-stage study tests a radioactive prostate cancer medicine that targets PSMA (a protein on prostate cancer cells). It aims to see how well the treatment works and how safe it is for men whose cancer has spread and shows PSMA on a scan.
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.